OncoMatch/Clinical Trials/NCT04725994
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Is NCT04725994 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including IDX-1197+XELOX and IDX-1197+Irinotecan for gastric cancer.
Treatment: IDX-1197+XELOX · IDX-1197+Irinotecan — This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Required: UGT1A1 any tested
Group 2 Part C, patients should have UGT1A1 genotype tested during or prior to screening
Excluded: HER2 (ERBB2) any tested
For Group 1, patients who are HER 2 positive [excluded]
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: palliative chemotherapy — palliative
Group 2, patients...who were treated ≥2 times with palliative chemotherapy before screening
Lab requirements
Kidney function
no uncontrolled renal illness
Liver function
no uncontrolled hepatic illness
Cardiac function
no severe or unstable angina, myocardial infarction or ischemia, symptomatic congestive heart failure, arterial or venous thromboembolism requiring coronary artery bypass graft or stent within the past 6 months or clinically significant cardiac dysrhythmia or New York Heart Association class II ~ IV heart disease within 6 months of randomization
uncontrolled hepatic, renal, or respiratory illness; severe or unstable angina, myocardial infarction or ischemia, symptomatic congestive heart failure, arterial or venous thromboembolism requiring coronary artery bypass graft or stent within the past 6 months or clinically significant cardiac dysrhythmia or New York Heart Association class II ~ IV heart disease within 6 months of randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC Norris Comp. Cancer Ctr Hospital · Los Angeles, California
- Hematology Oncology Clinic Baton Rouge / Sarah Cannon · Baton Rouge, Louisiana
- Dana Farber Cancer Institute · Boston, Massachusetts
- Astera Cancer Care · East Brunswick, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify